anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Primary care physicians (PCPs) often face a complex intersection of patient expectations, evidence, and policy that influences their care recommendations for acute low back pain (aLBP). The purpose of this study was to elucidate patterns of PCP orders for patients with aLBP, identify the most common patterns, and describe patient clinical and demographic characteristics associated with patterns of aLBP care.
METHODS: This prospective cohort study included 9574 aLBP patients presenting to 1 of 77 primary care practices in 4 geographic locations in the United States. We performed a cluster analysis of PCP orders extracted from electronic health records within the first 21 days of an initial visit for aLBP.
RESULTS: 1401 (15%) patients did not receive a PCP order related to back pain within the first 21 days of their initial visit. These patients predominantly had aLBP without leg pain, less back-related disability, and were at low-risk for persistent disability. Of the remaining 8146 patients, we found 4 distinct order patterns: combined nonpharmacologic and first-line medication (44%); second-line medication (39%); imaging (10%); and specialty referral (7%). Among all patients, 29% received solely 1 order from their PCP. PCPs more often combined different guideline concordant and discordant orders. Patients with higher self-reported disability and psychological distress were more likely to receive guideline discordant care.
CONCLUSION: Guideline discordant orders such as steroids and NSAIDS are often combined with guideline recommended orders such as physical therapy. Further defining patient, clinician, and health care setting characteristics associated with discordant care would inform targeted efforts for deimplementation initiatives.
Being diagnosed with Adolescent Idiopathic Scoliosis (AIS) between the ages of 10 and 18 group. Having a Cobb angle of 10 degrees or greater on a plain radiograph. Not having any known genetic disorders. Not having any diseases known to play a role in the etiology of scoliosis (degenerative, neuromuscular, congenital scoliosis, etc., are excluded).
MIEBO ®(perfluorohexyloctane ophthalmic solution) is a sterile, clear and colorless liquid containing 100% perfluorohexyloctane, for topical ophthalmic use. 

The active ingredient is 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane and is a semifluorinated alkane. It has a molecular formula of C 14H 17F 13and a molecular weight of 432.26 g/mol. The chemical structure is: 

Perfluorohexyloctane is practically immiscible with water. It is miscible with ethanol and most

organic solvents. Each multiple-dose bottle contains 3 mL of perfluorohexyloctane, 1.338 g/mL as a clear and colorless liquid.
In a one year (thirteen 28-day cycles) multicenter open-label clinical trial, 1,270 women 18 to 35 years of age, were studied to assess the efficacy of Lo Loestrin Fe, completing the equivalent of 12,482 28-day evaluable cycles of exposure. The racial demographic of all enrolled women was: Caucasian (74.9 percent), African-American (11.8 percent), Hispanic (9.8 percent), Asian (1.3 percent), and Other (2.2 percent). Women with body mass index (BMI) greater than 35 kg/m2 were excluded from the study. The weight range for those women treated was 89 to 260 lbs., with a mean weight of 150 lbs. Among the women in the trial, 51 percent had not used hormonal contraception immediately prior to enrolling in this study. Of treated women, 13.7 percent were lost to follow-up, 10.7 percent discontinued due to an adverse event, and 8.9 percent discontinued by withdrawing their consent.

The pregnancy rate (Pearl Index [PI]) in women 18 to 35 years of age was 2.92 pregnancies per 100 women-years of use (95 percent confidence interval 1.94 – 4.21), based on 28 pregnancies that occurred after the onset of treatment and extending through the 7 days following the last dose of Lo Loestrin Fe. Cycles in which conception did not occur, but which included the use of backup contraception, were not included in the calculation of the PI. The PI includes women who did not take the drug correctly.
PURPOSE: A composition Angelica utilis makino extract is provided to suppress acetylcholine esterase, to improve learning ability, and to treat neurodegenerative diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating neurodegenerative diseases contains Angelica utilis makino extract as an active ingredient. The Angelica utilis makino extract is a crude extract, non-polar solvent soluble extract, or polar solvent soluble extract. The crude extract is isolates using water, methanol, ethanol, butanol, or mixture solvent thereof. A health food for preventing and treating neurodegenerative diseases contains Angelica utilis makino extract as an active ingredient. The health food is manufactured in the form of powder, granule, tablet, capsule, or beverage.
Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) calculation and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
Patients receive sonidegib PO QD on days 1-8, and pembrolizumab IV over 30 minutes on day 8. Treatment repeats every 21 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Conclusions drawn from data gathered in Arm 1 will be given to the participant's prosthetist, along with their bioimpedance data from Arm 2, to inform the practitioner's decision on when a modification to the socket is warranted. The results will be compared to those of Arm 3.
OBJECTIVES: Forkhead box P3 (FOXP3) gene polymorphisms have been evaluated in many autoimmune diseases, including Graves' disease (GD), in different populations. However, those polymorphisms have not been analyzed in GD or Graves' ophthalmopathy (GO) in the Turkish population. In this study, we aimed to evaluate the frequency of FOXP3 polymorphisms in GD with or without ophthalmopathy in a Turkish population.
MATERIALS AND METHODS: The study included 100 patients with GO, 74 patients with GD without ophthalmopathy, and 100 age- and sex-matched healthy controls. In all study participants, rs3761547 (-3499 A/G), rs3761548 (-3279 C/A), and rs3761549 (-2383 C/T) single nucleotide polymorphisms (SNPs) were detected using the polymerase chain reaction-restriction fragment length polymorphism method. The chi-square test was used to evaluate genotype and allele frequencies. Odds ratios and 95% confidence intervals were calculated for genotype and allele risks.
RESULTS: In the patient group (including GD with or without ophthalmopathy), the rs3761548 AC and AA genotype and rs3761549 CT genotype were significantly more frequent than in the control group (all p<0.05). No genotypic and allelic differences were observed for rs3761547 between the patient and control groups (all p>0.05). There was no statistically significant difference between the GO and GD without ophthalmopathy groups concerning the allele and genotype frequencies of all three FOXP3 SNPs (all p>0.05).
CONCLUSION: The AC and AA genotypes of rs3761548 (-3279) and CT genotype of rs3761549 (-2383 C/T) were shown to be possible risk factors for GD development in the Turkish population. However, none of the three SNPs was shown to be associated with the development of GO in patients with GD.
Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg).
Acute high-output heart failure (HOHF) with pulmonary hypertension and liver injury caused by amlodipine poisoning is very rare. We report a 52-year-old woman who suffered from severe shock after an overdose of amlodipine. Hemodynamic monitoring showed that while her left ventricular systolic function and cardiac output were elevated, her systemic vascular resistance decreased significantly. At the same time, the size of her right heart, her central venous pressure, and the oxygen saturation of her central venous circulation all increased abnormally. The patient's circulatory function and right ventricular dysfunction gradually improved after large doses of vasopressors and detoxification measures. However, her bilirubin and transaminase levels increased significantly on hospital day 6, with a CT scan showing patchy, low-density areas in her liver along with ascites. After liver protective treatment and plasma exchange, the patient's liver function gradually recovered. A CT scan 4 months later showed all her liver abnormalities, including ascites, had resolved. The common etiologies of HOHF were excluded in this case, and significantly reduced systemic vascular resistance caused by amlodipine overdose was thought to be the primary pathophysiological basis of HOHF. The significant increase in venous return and pulmonary blood flow is considered to be the main mechanism of right ventricular dysfunction and pulmonary hypertension. Hypoxic hepatitis caused by a combination of hepatic congestion and distributive shock may be the most important factors causing liver injury in this patient. Whether amlodipine has other mechanisms leading to HOHF and pulmonary hypertension needs to be further studied. Considering the significant increase of right heart preload, aggressive fluid resuscitation should be done very cautiously in patients with HOHF and shock secondary to amlodipine overdose.
<P>PROBLEM TO BE SOLVED: To minimize the risk of breakdown, even if the dimensions of the sample chamber and electrodes become further smaller.  <P>SOLUTION: The removable data storage device for a measuring instrument which uses a test strip to measure the concentration of an object to be analyzed in a liquid sample is configured, to include a carrier having a proximal and distal end, and including a circuit board. The circuit board has electrical contacts, including a ground contact and a voltage supply contact electrically connected to the measuring instrument at predetermined positions. The circuit board includes a nonvolatile memory storing data used by the measuring instrument. The data includes constants used by machine language instructions stored in the memory of the measuring instrument. When the removable data storage device is inserted into the measuring instrument in the preferred orientation, the ground contact becomes electrically connected to the measuring instrument before the voltage supply contact; and when the removable data storage device is removed from the measuring instrument, the ground contact becomes electrically disconnected from the measuring instrument after the voltage supply contact.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention designs an 18F labeled p-nitro benzoyl amino acid compound, which is characterized by simultaneously having 2-18F-4-nitro-benzoyl structure and an alpha-amino acid structure, and a substituent R positioned on a carboxyl alpha position, wherein the substituent R comprises hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, 2-methylthio-ethyl, carboxyethyl, carboxy-propyl, phenyl and imidazole methyl. Two end structures are directly connected with each other through an amido bond. The compound has a structure formula A. The compound can be synthesized simply and has a high labeling rate. The compound is absorbed for a large amount in tumor tissues and is eliminated slowly, but in normal tissues and blood, the compound is absorbed for a small amount or is eliminated quickly. The compound has a very high tumor/blood specific value and a very high tumor/normal tissue specific value, in particular a very high brain normal tissue specific value, and has a high discrimination degree of tumor and brain background. The invention also relates to the application of the compound as a PET brain tumor imaging agent.
Clinical healthy volunteers will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME IMMUN®. Whenever possible, the volunteers will receive complete primary vaccination with a third dose of TBE vaccine FSME IMMUN® (study visit 9 - 12 months after the first vaccination).
Connected and autonomous vehicles (CAVs) will greatly impact the lives of individuals with visual impairments, but how they differ in expectations compared to sighted individuals is not clear. The present research reports results based on survey responses from 114 visually impaired participants and 117 panel recruited participants without visual impairments, from Germany. Their attitudes towards autonomous vehicles and their expectations for consequences of wide-spread adoption of CAVs are assessed. Results indicate significantly more positive CAV attitudes in participants with visual impairments compared to those without visual impairments. Mediation analyses indicate that visually impaired individuals' more positive CAV attitudes (compared to sighted individuals') are largely explained by higher hopes for independence, and more optimistic expectations regarding safety and sustainability. Policy makers should ensure accessibility without sacrificing goals for higher safety and lower ecological impact to make CAVs an acceptable inclusive mobility solution.
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an unignorable event in the management of chronic obstructive pulmonary disease. It is crucial to seek for effective management strategy. Compound sodium chlolate and aminophylline tablets are one of the most widely used drugs for the treatment of bronchial asthma and chronic bronchitis. Compared with the local bronchodilator recommended by the guidelines, it has the advantages of convenient use and good patient compliance. For the purpose of optimize the management of acute exacerbation of chronic obstructive pulmonary disease and provide more convenient options, we compared the efficacy of combined compound sodium chlolate and aminophylline tablets with nebulized ipratropium bromide inhalation plus systemic glucocorticoids in the treatment of chronic obstructive pulmonary disease ranging from moderate degree to severe degree. We hope this research would benefit patients with chronic obstructive pulmonary, especially those in the grassroots.
Two Aim 2 practices are selected by each of their 5 affiliated PBRNs based upon willingness to participate and variability of primary care practice type within the PBRN. Differences in practice size, staffing, ownership, prior quality improvement engagement, geography, patient population socioeconomic status (SES) or languages spoken are among the among the selection criteria the PBRNs will utilize to choose.
Daily oral administration of bisoprolol 0.625 mg tablet once a day should be given (Step 1). If tolerability is confirmed by an investigator, the dose should be increased to 1.25 mg (bisoprolol 0.625 mg, 2 tablets; or bisoprolol 2.5 mg, half tablet; once daily) (Step 2). In the same manner, the doses should be increased to 2.5 mg (bisoprolol 2.5 mg, 1 tablet; or bisoprolol 5 mg, half tablet; once daily, Step 3), to 3.75 mg (bisoprolol 2.5 mg, 1.5 tablets once daily, Step 4), and to 5 mg (bisoprolol 2.5 mg, 2 tablets; or bisoprolol 5 mg, 1 tablet; once daily, Step 5).
Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Systane, 40 microliters) will be administered using the same procedure protocol.
Each subject in the experimental group was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/- 10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, pause 2 After two weeks, the two groups crossed over and carried out 4 weeks of intervention.
PCT No. PCT/EP94/03882 Sec. 371 Date May 30, 1996 Sec. 102(e) Date May 30, 1996 PCT Filed Nov. 23, 1994 PCT Pub. No. WO95/15186 PCT Pub. Date Jun. 8, 1995The invention is concerned with a process for counteracting smoke malodour wherein enclosed air spaces wherein smoke maladour is present, or substrates on which smoke malodour has deposited are brought in contact with one or more perfumery aldehydes of the class I according to general structure, wherein R1 and R2 each may be: hydrogen, alkyl, hydroxyl or alkoxy, or together may be methylenedioxy or with a perfume containing such aldehydes. Preferably the perfume also contains one or more perfumery aldehydes of class according to general structure, wherein R1 is a phenyl ring optionally substituted with an alkyl group, R2 represents hydrogen or both R2 taken together represent a double bond, and R3 is hydrogen or an alkyl chain with 1 to 6 carbon atoms. The smoke malodour counteracting perfumes preferably contain at least 3.5% w/w of class I aldehydes and at least 10% w/w of class II aldehydes. The perfumes are suitable for incorporation in air fresheners, and products for treatment or cleaning of skin, hair, clothing, curtains, wall paper and floor cover.
A traditional Chinese medicine formula for treating cyclomastopathy comprises the following components by weight percentage: 8.6-12.8 percent of astragalus, 12.8-19.3 percent of dandelion, 4.3-6.4 percent of paris, 2.8-4.3 percent of unripe tangerine peel, 2.8-4.3 percent of orange leaf, 4.3-6.4 percent of semen citri reticulatae, 2.8-4.3 percent of pangolin, 2.8-4.3 percent of silkworm, 5.7-8.6 percent of prunella, 5.7-8.6 percent of oyster, 4.3-6.4 percent of mix-fried turtle shell, 2.8-4.3 percent of peach kernel, 2.8-4.3 percent of red peony, 2.8-4.3 percent frankincense, 2.8-4.3 percent of myrrh, 2.8-4.3 percent of sparganium, 4.3-6.4 percent of Curcuma zedoaria (Christm.) Rosc, and 4.3-6.4 percent of forsythia. The components in the traditional Chinese medicine formula are decocted in water and taken, and a period of treatment includes 10 days. The traditional Chinese medicine has the effects of clearing heat, resolving toxin, coursing liver, rectifying qi, transfering phlegm, dispersing stasis, softening hardness and dissipating bind, and is an ideal medicine for treating the cyclomastopathy. The traditional Chinese medicine formula treats 64 patients and cures 50 patients, and the cure rate is 78.1 percent; the illness states of 10 patients are improved, and the improvement rate is 15.6 percent; four patients are not cured, and the failure rate is 6.3 percent. The total actovoty ratio is 93.7 percent.
BACKGROUND: Myceliophthora heterothallica belonging to Myceliophthora is considered as an environmental fungus and has not been reported to be pathogenic or colonizing in recent literature. The present case firstly reports a ventilation-associated pneumonia caused by Myceliophthora heterothallica among the aged adult.
CASE PRESENTATION: A 67-years-old Asian female patient suffering from a sudden disturbance of consciousness for 3 h was admitted to our hospital. Cardiac arrest occurred during emergency transport, and sinus rhythm was restored after cardiopulmonary resuscitation. Invasive mechanical ventilation was given to this patient for respiratory failure. After mechanical ventilation, the lung CT images showed multiple cuneiform nodules arranging subpleural accompanying with ground-glass opacity. On the 5th day of mechanical ventilation, Myceliophthora heterothallica was cultured from endotracheal aspirates. Two methods, namely automatic microbial identification system and internal transcribed spacer sequencing were employed to identify this fungus. The present case firstly uncovered the colonization ability and pathogenicity of Myceliophthora heterothallica in the respiratory tract. After 28d of treatment with piperacillin-tazobactam, this patient weaned from the ventilator and recovered from consciousness with lung infection disappearance.
CONCLUSIONS: This is the first case report of ventilation-associated pneumonia in the aged patient caused by Myceliophthora heterothallica. This current case is worth for the clinical diagnosis and treatment of Myceliophthora heterothallica infection, and also enriches new pathogenic species found of thermothelomyces species.
BACKGROUND: Omphalocele is an abnormality in which fetal abdominal organs protrude through the abdominal wall.
CASE REPORT: We report the case of a 13-year-old female with a history of omphalocele repair who presented with acute periumbilical pain, nausea, and vomiting. A computed tomography scan showed a para-ovarian cyst and mild dilation of the small bowel. During laparoscopy, the right ovary and fallopian tube were detached from the uterus and located behind the cecum. Despite this displacement, the ovary appeared to have retained functionality with intact blood supply. We hypothesize that surgical repair led to pelvic adhesion that caused torsion and avulsion of the fallopian tube and utero-ovarian ligament that led to the displacement.
CONCLUSION: This anatomical change should be considered in surgical patients with a history of omphalocele repair.
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent disease progression to accelerated phase-CML or blast phase-CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase-CML.
Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, mapped on the 3p chromosome, cloned into recombinant vectors, used to prepare recombinant cells and sequenced. The FANCD2 gene sequence provides probes and primers for screening patients in genetic based test and for diagnosing Fanconi anemia and cancer. It has also been possible to target the FANCD2 gene in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. Vectors are described for use in gene therapy. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the mono-ubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact FA pathway. The FANCD2 has been localized to the nucleus and is associated with BRCA 1 foci.
Patients will receive first line docetaxel until disease progression according to treating clinician or completion of 10 cycles. Patients and treating clinicians will not be disclosed to the results of CTC determinations.